Sotuletinib (BLZ945) is an experimental drug in development for the treatment of amyotrophic lateral sclerosis (ALS). It works as a colony-stimulating factor 1 (CSF1) receptor inhibitor.[1][2][3]
References
edit- ^ Pognan, François; Buono, Chiara; Couttet, Philippe; Galarneau, Jean-René; Timsit, Yoav; Wolf, Armin (29 October 2022). "Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib". Current Research in Toxicology. 3: 100091. doi:10.1016/j.crtox.2022.100091. ISSN 2666-027X. PMC 9637862. PMID 36353522.
- ^ Thongchot, Suyanee; Duangkaew, Supani; Yotchai, Wasan; Maungsomboon, Sorranart; Phimolsarnti, Rapin; Asavamongkolkul, Apichat; Thuwajit, Peti; Thuwajit, Chanitra; Chandhanayingyong, Chandhanarat (2 December 2022). "Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis". Human Cell. 36 (1): 456–467. doi:10.1007/s13577-022-00823-0. PMC 9813176. PMID 36456782.
- ^ Martinez-Gonzalez, Loreto; Martinez, Ana (1 February 2023). "Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis". Expert Opinion on Investigational Drugs. 32 (2): 141–160. doi:10.1080/13543784.2023.2178416. hdl:10261/308825. PMID 36762798.